Perturb.ai

8 million brain cells. 32 minutes. A new frontier in medicine.

In less than a year, PerturbAI built a proprietary AI-native drug discovery engine, created 6 genomic maps, revealing how genes influence health and disease in living systems.

Now, together with @OpenAI and @ScrippsResearch, we've uncovered 11,000 biological insights and ~100 promising leads using frontier AI in just 32 minutes.

We're expanding our partnership into drug-target discovery, bringing us closer to understanding disease and developing new medicines.

Better biology. Better targets. Better medicines.

Learn more: perturb.ai/news/perturbai…

Read the full blog here: openai.com/index/scaling-…

Is AI making drug discovery more efficient?

According to a recently published paper in Nature Reviews Drug Discovery, not yet. And as @axios highlighted this week, a key reason is that today's AI is trained on data that does not translate into clinically successful targets. 

This is why we founded PerturbAI. By generating large-scale causal data directly in living organs, we can identify targets more likely to translate and make better therapeutic decisions early, before years and millions are spent downstream. 

Read the full Axios article here: finance.yahoo.com/healthcare/art…

Learn more about how PerturbAI is addressing this challenge: perturb.ai

#AI #Biotech #DrugDiscovery #CRISPR #Genomics

It was great to hear former Akero Therapeutics CEO Andrew Cheng unpack their landmark deal with Novo Nordisk at #BIO2026.

From leading Akero through its $5.2B acquisition to his decades of clinical leadership at Gilead Sciences, Andrew's track record of scaling biotech innovation is unmatched.

We are incredibly fortunate to have Andrew bringing that caliber of industry foresight to PerturbAI as an advisor. His expertise is an invaluable asset as we work to build the next generation of AI-enabled therapeutics.

#Biotech #Innovation #DrugDiscovery #AI

PerturbAI is taking the stage at HardTech LIVE during San Francisco’s @deeptechweek on June 26!

Our co-founder and CEO, Grace Zheng, will share how PerturbAI is building biology's causal data engine, and using AI to turn insight into better medicines.

A few VIP spots are left for this event. Claim one here: deep-tech-week.com/sf-2026/events…
#DeepTechWeek #HardTech #AI #Genomics #DrugDiscovery

Last week, we wrote about our proprietary AI platform that powers therapeutic discovery at PerturbAI.

Today, we're sharing public tools and workflows we developed together with @NVIDIAHealth that make it easier to explore and analyze our Whole-Brain CRISPR Atlas, now downloaded more than 30,000 times since we released it in March.

perturb.ai/news-0623-publ…

🧠🧬✨